ClinicalTrials.gg
Not yet recruitingNCT07534410CPET-PCHDUpdated Apr 16, 2026

The Prognostic Value of Cardiopulmonary Exercise Testing Parameters in Patients With Coronary Heart Disease: A Retrospective Cohort Study(CPETPCAD)

An observational study in Coronary Heart Disease (CHD), sponsored by Xinjiang Medical University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Xinjiang Medical University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
15,000
Ages
18 Years and older
Sex
All
01

Study summary

Parameters related to cardiopulmonary exercise testing (CPET) are important objective indicators for evaluating cardiopulmonary function in patients with coronary heart disease. However, the clinical application of CPET parameters in the prognostic assessment of patients with coronary heart disease remains unclear. This is a retrospective cohort study designed to systematically collect real-world clinical data and long-term follow-up outcomes of patients with coronary heart disease. Through standardized follow-up, this study will investigate the association between CPET parameters and adverse clinical outcomes in patients with coronary heart disease, as well as the relevant risk factors.

02

Conditions studied

  • Coronary Heart Disease (CHD)

Browse trials for

03

In context

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

This study's planned enrollment of 15,000 is above the median of 916 across 478 observational studies indexed under Coronary Disease.

Browse Coronary Disease studies →

Lead sponsor

Xinjiang Medical University is the lead sponsor of 21 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients diagnosed with coronary heart disease in our hospital and who have completed cardiopulmonary exercise testing.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Our hospital has diagnosed coronary heart disease and conducted cardiopulmonary exercise tests.
  2. Patients with complete clinical data.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled heart failure ( classification Ⅲ-IV grade).
  2. Complications, such as moderate to severe anemia, tumors and lung diseases.
  3. Complicated with valvular heart disease.
  4. Unable to reach the anaerobic threshold during exercise.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
15,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Coronary Heart Disease Cohort
06

What researchers measure

Primary outcomes

  1. Cumulative incidence of Major Adverse Cardiovascular Events (MACE)

    The proportion of patients who experience an adjudicated Major Adverse Cardiovascular Event (MACE), defined as a composite endpoint consisting of non-fatal myocardial infarction, non-fata

    Time frame: 1 year

Secondary outcomes

  1. All-cause mortality

    Record of deaths from any cause during follow-up. Confirmed by medical records, family follow-up, or national death registration systems.

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Zhang N, Maitudi M, Lu W. Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial. Clin Ther. 2026 Jun 30:S0149-2918(26)00216-X. doi: 10.1016/j.clinthera.2026.06.004. Online ahead of print. PubMed 42379943 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Jan 2027, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Apr 16, 2026
StartEst.
Apr 7, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jun 30, 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07534410
Lead sponsor
Xinjiang Medical University
Responsible party
Xiang Xie (Professor, Xinjiang Medical University) — Principal investigator
First posted
Apr 16, 2026
Start date
Apr 7, 2026 (estimated)
Primary completion
Jan 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Xiang Xie, PhD
Contact
xiangxie999@sina.com
+86-991-4366892
Xiang Xie, PhD
study chair · First Affiliated Hospital of Xinjiang Medical University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion